Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference

P. Nestby, A. N M Schoffelmeer, J. R. Homberg, G. Wardeh, T. J. De Vries, A. H. Mulder, L. J M J Vanderschuren

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

It has been postulated that opioid systems in the brain may play a role in ethanol reinforcement. In this respect, μ- and δ-opioid receptors may mediate the rewarding effects whereas κ receptors are thought to mediate the aversive effects of opioids. Accordingly, long-acting benzomorphans such as bremazocine, that simultaneously act as μ and δ receptor antagonists and κ receptor agonists may be particularly effective in reducing ethanol self- administration. Therefore, we studied the effect of bremazocine on oral ethanol self-administration in rats using a paradigm [unrestricted free- choice drinking of 10% (v/v) ethanol], previously shown to cause long-term neuroadaptations in the nucleus accumbens and caudate putamen. Bremazocine (0.1 mg/kg, once daily for five consecutive days) reduced ethanol drinking by about 50% during the active period of the animals, whereas the intake of sucrose (3-10% w/v) was affected neither in naive nor in ethanol-experienced rats. This effect of bremazocine appeared not to be secondary to its acute sedative effect or the slight increase in total fluid consumption. Unlike bremazocine, the selective κ-opioid receptor agonist U50,488H (10mg/kg, once daily) inhibited ethanol drinking only during the first of 5 treatment days and the opioid receptor antagonist naltrexone (0.3-10 mg/kg, once daily) only caused a modest (about 20%) suppression of ethanol drinking during the first hours after drug injection. Thus, bremazocine appears to be far more potent than the clinically applied drug naltrexone in this respect. Our data further support the role of opioid receptors in ethanol reinforcement and indicate that long-acting mixed-action opioids such as bremazocine may be useful as adjuvants for the clinical management of ethanol addiction.

Original languageEnglish
Pages (from-to)309-317
Number of pages9
JournalPsychopharmacology
Volume142
Issue number3
DOIs
Publication statusPublished - 7 May 1999

Cite this

Nestby, P., Schoffelmeer, A. N. M., Homberg, J. R., Wardeh, G., De Vries, T. J., Mulder, A. H., & Vanderschuren, L. J. M. J. (1999). Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference. Psychopharmacology, 142(3), 309-317. https://doi.org/10.1007/s002130050894
Nestby, P. ; Schoffelmeer, A. N M ; Homberg, J. R. ; Wardeh, G. ; De Vries, T. J. ; Mulder, A. H. ; Vanderschuren, L. J M J. / Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference. In: Psychopharmacology. 1999 ; Vol. 142, No. 3. pp. 309-317.
@article{fd9400e0acbd4adc9b31e19fc92e5109,
title = "Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference",
abstract = "It has been postulated that opioid systems in the brain may play a role in ethanol reinforcement. In this respect, μ- and δ-opioid receptors may mediate the rewarding effects whereas κ receptors are thought to mediate the aversive effects of opioids. Accordingly, long-acting benzomorphans such as bremazocine, that simultaneously act as μ and δ receptor antagonists and κ receptor agonists may be particularly effective in reducing ethanol self- administration. Therefore, we studied the effect of bremazocine on oral ethanol self-administration in rats using a paradigm [unrestricted free- choice drinking of 10{\%} (v/v) ethanol], previously shown to cause long-term neuroadaptations in the nucleus accumbens and caudate putamen. Bremazocine (0.1 mg/kg, once daily for five consecutive days) reduced ethanol drinking by about 50{\%} during the active period of the animals, whereas the intake of sucrose (3-10{\%} w/v) was affected neither in naive nor in ethanol-experienced rats. This effect of bremazocine appeared not to be secondary to its acute sedative effect or the slight increase in total fluid consumption. Unlike bremazocine, the selective κ-opioid receptor agonist U50,488H (10mg/kg, once daily) inhibited ethanol drinking only during the first of 5 treatment days and the opioid receptor antagonist naltrexone (0.3-10 mg/kg, once daily) only caused a modest (about 20{\%}) suppression of ethanol drinking during the first hours after drug injection. Thus, bremazocine appears to be far more potent than the clinically applied drug naltrexone in this respect. Our data further support the role of opioid receptors in ethanol reinforcement and indicate that long-acting mixed-action opioids such as bremazocine may be useful as adjuvants for the clinical management of ethanol addiction.",
keywords = "Bremazocine, Ethanol, Naltrexone, Sucrose, U50,488H",
author = "P. Nestby and Schoffelmeer, {A. N M} and Homberg, {J. R.} and G. Wardeh and {De Vries}, {T. J.} and Mulder, {A. H.} and Vanderschuren, {L. J M J}",
year = "1999",
month = "5",
day = "7",
doi = "10.1007/s002130050894",
language = "English",
volume = "142",
pages = "309--317",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

Nestby, P, Schoffelmeer, ANM, Homberg, JR, Wardeh, G, De Vries, TJ, Mulder, AH & Vanderschuren, LJMJ 1999, 'Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference' Psychopharmacology, vol. 142, no. 3, pp. 309-317. https://doi.org/10.1007/s002130050894

Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference. / Nestby, P.; Schoffelmeer, A. N M; Homberg, J. R.; Wardeh, G.; De Vries, T. J.; Mulder, A. H.; Vanderschuren, L. J M J.

In: Psychopharmacology, Vol. 142, No. 3, 07.05.1999, p. 309-317.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Bremazocine reduces unrestricted free-choice ethanol self- administration in rats without affecting sucrose preference

AU - Nestby, P.

AU - Schoffelmeer, A. N M

AU - Homberg, J. R.

AU - Wardeh, G.

AU - De Vries, T. J.

AU - Mulder, A. H.

AU - Vanderschuren, L. J M J

PY - 1999/5/7

Y1 - 1999/5/7

N2 - It has been postulated that opioid systems in the brain may play a role in ethanol reinforcement. In this respect, μ- and δ-opioid receptors may mediate the rewarding effects whereas κ receptors are thought to mediate the aversive effects of opioids. Accordingly, long-acting benzomorphans such as bremazocine, that simultaneously act as μ and δ receptor antagonists and κ receptor agonists may be particularly effective in reducing ethanol self- administration. Therefore, we studied the effect of bremazocine on oral ethanol self-administration in rats using a paradigm [unrestricted free- choice drinking of 10% (v/v) ethanol], previously shown to cause long-term neuroadaptations in the nucleus accumbens and caudate putamen. Bremazocine (0.1 mg/kg, once daily for five consecutive days) reduced ethanol drinking by about 50% during the active period of the animals, whereas the intake of sucrose (3-10% w/v) was affected neither in naive nor in ethanol-experienced rats. This effect of bremazocine appeared not to be secondary to its acute sedative effect or the slight increase in total fluid consumption. Unlike bremazocine, the selective κ-opioid receptor agonist U50,488H (10mg/kg, once daily) inhibited ethanol drinking only during the first of 5 treatment days and the opioid receptor antagonist naltrexone (0.3-10 mg/kg, once daily) only caused a modest (about 20%) suppression of ethanol drinking during the first hours after drug injection. Thus, bremazocine appears to be far more potent than the clinically applied drug naltrexone in this respect. Our data further support the role of opioid receptors in ethanol reinforcement and indicate that long-acting mixed-action opioids such as bremazocine may be useful as adjuvants for the clinical management of ethanol addiction.

AB - It has been postulated that opioid systems in the brain may play a role in ethanol reinforcement. In this respect, μ- and δ-opioid receptors may mediate the rewarding effects whereas κ receptors are thought to mediate the aversive effects of opioids. Accordingly, long-acting benzomorphans such as bremazocine, that simultaneously act as μ and δ receptor antagonists and κ receptor agonists may be particularly effective in reducing ethanol self- administration. Therefore, we studied the effect of bremazocine on oral ethanol self-administration in rats using a paradigm [unrestricted free- choice drinking of 10% (v/v) ethanol], previously shown to cause long-term neuroadaptations in the nucleus accumbens and caudate putamen. Bremazocine (0.1 mg/kg, once daily for five consecutive days) reduced ethanol drinking by about 50% during the active period of the animals, whereas the intake of sucrose (3-10% w/v) was affected neither in naive nor in ethanol-experienced rats. This effect of bremazocine appeared not to be secondary to its acute sedative effect or the slight increase in total fluid consumption. Unlike bremazocine, the selective κ-opioid receptor agonist U50,488H (10mg/kg, once daily) inhibited ethanol drinking only during the first of 5 treatment days and the opioid receptor antagonist naltrexone (0.3-10 mg/kg, once daily) only caused a modest (about 20%) suppression of ethanol drinking during the first hours after drug injection. Thus, bremazocine appears to be far more potent than the clinically applied drug naltrexone in this respect. Our data further support the role of opioid receptors in ethanol reinforcement and indicate that long-acting mixed-action opioids such as bremazocine may be useful as adjuvants for the clinical management of ethanol addiction.

KW - Bremazocine

KW - Ethanol

KW - Naltrexone

KW - Sucrose

KW - U50,488H

UR - http://www.scopus.com/inward/record.url?scp=0032925295&partnerID=8YFLogxK

U2 - 10.1007/s002130050894

DO - 10.1007/s002130050894

M3 - Article

VL - 142

SP - 309

EP - 317

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -